Venus Remedies’ stock jumped 6% following the announcement of marketing authorization for Pemetrexed 500mg, a chemotherapy agent used to treat lung cancer and mesothelioma, in the Philippines.
This approval represents a significant step forward in Venus Remedies’ strategy to expand its footprint in the rapidly growing Southeast Asian pharmaceutical market.
The stock opened at ₹325.30, hitting a high of ₹349.70 and a low of ₹313.75, with a 52-week high of ₹430.00 and a low of ₹281.10.
As of 1:26 pm, Venus Remedies shares were trading 6.34% higher at Rs 343.65 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
